175 related articles for article (PubMed ID: 34830866)
1. Oncogenic KRAS Requires Complete Loss of BAP1 Function for Development of Murine Intrahepatic Cholangiocarcinoma.
Marcus R; Ferri-Borgogno S; Hosein A; Foo WC; Ghosh B; Zhao J; Rajapakshe K; Brugarolas J; Maitra A; Gupta S
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830866
[TBL] [Abstract][Full Text] [Related]
2. Nuclear BAP1 loss is common in intrahepatic cholangiocarcinoma and a subtype of hepatocellular carcinoma but rare in pancreatic ductal adenocarcinoma.
Mosbeh A; Halfawy K; Abdel-Mageed WS; Sweed D; Rahman MHA
Cancer Genet; 2018 Aug; 224-225():21-28. PubMed ID: 29778232
[TBL] [Abstract][Full Text] [Related]
3. Combination of Kras activation and PTEN deletion contributes to murine hepatopancreatic ductal malignancy.
Lin YK; Fang Z; Jiang TY; Wan ZH; Pan YF; Ma YH; Shi YY; Tan YX; Dong LW; Zhang YJ; Wang HY
Cancer Lett; 2018 May; 421():161-169. PubMed ID: 29452147
[TBL] [Abstract][Full Text] [Related]
4. Intrahepatic cholangiocarcinoma frequently shows loss of BAP1 and PBRM1 expression, and demonstrates specific clinicopathological and genetic characteristics with BAP1 loss.
Misumi K; Hayashi A; Shibahara J; Arita J; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M
Histopathology; 2017 Apr; 70(5):766-774. PubMed ID: 27864835
[TBL] [Abstract][Full Text] [Related]
5. Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma.
Joseph NM; Tsokos CG; Umetsu SE; Shain AH; Kelley RK; Onodera C; Bowman S; Talevich E; Ferrell LD; Kakar S; Krings G
J Pathol; 2019 Jun; 248(2):164-178. PubMed ID: 30690729
[TBL] [Abstract][Full Text] [Related]
6. Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma.
O'Dell MR; Huang JL; Whitney-Miller CL; Deshpande V; Rothberg P; Grose V; Rossi RM; Zhu AX; Land H; Bardeesy N; Hezel AF
Cancer Res; 2012 Mar; 72(6):1557-67. PubMed ID: 22266220
[TBL] [Abstract][Full Text] [Related]
7. BAP1 acts as a tumor suppressor in intrahepatic cholangiocarcinoma by modulating the ERK1/2 and JNK/c-Jun pathways.
Chen XX; Yin Y; Cheng JW; Huang A; Hu B; Zhang X; Sun YF; Wang J; Wang YP; Ji Y; Qiu SJ; Fan J; Zhou J; Yang XR
Cell Death Dis; 2018 Oct; 9(10):1036. PubMed ID: 30305612
[TBL] [Abstract][Full Text] [Related]
8. A novel mouse model of intrahepatic cholangiocarcinoma induced by liver-specific Kras activation and Pten deletion.
Ikenoue T; Terakado Y; Nakagawa H; Hikiba Y; Fujii T; Matsubara D; Noguchi R; Zhu C; Yamamoto K; Kudo Y; Asaoka Y; Yamaguchi K; Ijichi H; Tateishi K; Fukushima N; Maeda S; Koike K; Furukawa Y
Sci Rep; 2016 Apr; 6():23899. PubMed ID: 27032374
[TBL] [Abstract][Full Text] [Related]
9. Mouse model of proximal colon-specific tumorigenesis driven by microsatellite instability-induced Cre-mediated inactivation of Apc and activation of Kras.
Kawaguchi Y; Hinoi T; Saito Y; Adachi T; Miguchi M; Niitsu H; Sasada T; Shimomura M; Egi H; Oka S; Tanaka S; Chayama K; Sentani K; Oue N; Yasui W; Ohdan H
J Gastroenterol; 2016 May; 51(5):447-57. PubMed ID: 26361962
[TBL] [Abstract][Full Text] [Related]
10. Case Report: BAP1 Mutation and RAD21 Amplification as Predictive Biomarkers to PARP Inhibitor in Metastatic Intrahepatic Cholangiocarcinoma.
Sabbatino F; Liguori L; Malapelle U; Schiavi F; Tortora V; Conti V; Filippelli A; Tortora G; Ferrone CR; Pepe S
Front Oncol; 2020; 10():567289. PubMed ID: 33330039
[TBL] [Abstract][Full Text] [Related]
11. Somatic mutation and expression of BAP1 in hepatocellular carcinoma: an indicator for ferroptosis and immune checkpoint inhibitor therapies.
Yan YC; Meng GX; Ding ZN; Liu YF; Chen ZQ; Yan LJ; Yang YF; Liu H; Yang CC; Dong ZR; Hong JG; Li T
J Cancer; 2022; 13(1):88-101. PubMed ID: 34976173
[TBL] [Abstract][Full Text] [Related]
12. GNAS(R201H) and Kras(G12D) cooperate to promote murine pancreatic tumorigenesis recapitulating human intraductal papillary mucinous neoplasm.
Taki K; Ohmuraya M; Tanji E; Komatsu H; Hashimoto D; Semba K; Araki K; Kawaguchi Y; Baba H; Furukawa T
Oncogene; 2016 May; 35(18):2407-12. PubMed ID: 26257060
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic potential of IDH1R132C mutant in cholangiocarcinoma development in mice.
Ding N; Che L; Li XL; Liu Y; Jiang LJ; Fan B; Tao JY; Chen X; Ji JF
World J Gastroenterol; 2016 Feb; 22(6):2071-80. PubMed ID: 26877611
[TBL] [Abstract][Full Text] [Related]
14. Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.
Qiu W; Tang SM; Lee S; Turk AT; Sireci AN; Qiu A; Rose C; Xie C; Kitajewski J; Wen HJ; Crawford HC; Sims PA; Hruban RH; Remotti HE; Su GH
Gastroenterology; 2016 Jan; 150(1):218-228.e12. PubMed ID: 26408346
[TBL] [Abstract][Full Text] [Related]
15. The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.
Chong DQ; Zhu AX
Oncotarget; 2016 Jul; 7(29):46750-46767. PubMed ID: 27102149
[TBL] [Abstract][Full Text] [Related]
16. Differentially expressed gene profiles of intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and combined hepatocellular-cholangiocarcinoma by integrated microarray analysis.
Xue TC; Zhang BH; Ye SL; Ren ZG
Tumour Biol; 2015 Aug; 36(8):5891-9. PubMed ID: 25712376
[TBL] [Abstract][Full Text] [Related]
17. Preoperative metabolic tumor volume of intrahepatic cholangiocarcinoma measured by
Ikeno Y; Seo S; Iwaisako K; Yoh T; Nakamoto Y; Fuji H; Taura K; Okajima H; Kaido T; Sakaguchi S; Uemoto S
J Transl Med; 2018 Apr; 16(1):95. PubMed ID: 29642912
[TBL] [Abstract][Full Text] [Related]
18. Kras
Chung WC; Wang J; Zhou Y; Xu K
Oncoscience; 2017 Sep; 4(9-10):131-138. PubMed ID: 29142904
[TBL] [Abstract][Full Text] [Related]
19. Emergence of Intrahepatic Cholangiocarcinoma: How High-Throughput Technologies Expedite the Solutions for a Rare Cancer Type.
Shiao MS; Chiablaem K; Charoensawan V; Ngamphaiboon N; Jinawath N
Front Genet; 2018; 9():309. PubMed ID: 30158952
[TBL] [Abstract][Full Text] [Related]
20. Intrahepatic cholangiocarcinoma development in a patient with a novel BAP1 germline mutation and low exposure to asbestos.
Brandi G; Deserti M; Palloni A; Turchetti D; Zuntini R; Pedica F; Frega G; De Lorenzo S; Abbati F; Rizzo A; Di Marco M; Massari F; Tavolari S
Cancer Genet; 2020 Oct; 248-249():57-62. PubMed ID: 33093002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
